More competitors in the market doesn’t equate to lower prices
SAN FRANCISCO (MarketWatch) — If you’re looking for drug makers to
start discounting those pricey, $1,000-a-pill remedies for hepatitis C
soon, prepare to be disappointed.
Biopharmaceutical companies like Gilead Sciences Inc. aren’t showing any signs of
easing up on the drug prices that have incurred the wrath of insurers
and others in the health-care arena, who claim the makers of hepatitis C
remedies are gouging the public. It also doesn’t appear that more
competitors expected to come to market with their own hepatitis C
medications are overly concerned they’ll have trouble selling the drugs.
From what the drug makers are saying, cutting the price is not their highest priority.
Labels: drug pricing